Boehringer Ingelheim has partnered with Gubra, a specialized biotech company and preclinical CRO that specializes in peptide-based drug discovery for metabolic diseases, to launch phase 1 clinical trials for BI 3034701. This drug candidate is a long-acting peptide designed to target three different receptors associated with weight loss, offering a potential new avenue for tackling…
When size doesn’t matter: How Lilly and Novo Nordisk are outperforming pharma giants in value creation
The graphic above shows darker bubbles for companies with larger market caps as of March 25, 2024. Revenue and R&D spending figures are in USD. More data are available when hovering over a given company. After a COVID-19 rebound in public perception and willingness to explore novel modalities, the pharma industry faces mounting pressures…
GLP-1s, ADCs, AI and the future of pharma
Pharma’s potential breakthroughs in AI, ADCs, and GLP-1 receptor agonists raise a critical question: can innovation outpace the relentless rise of chronic disease? The IQVIA Institute for Human Data Science sheds light on this theme, among many others, in its 80-page Global Trends in R&D 2024 report. Pillar 1: GLP-1 receptor agonists targeting metabolic disease…
Beyond diabetes and obesity: Can GLP-1 therapies also transform chronic disease treatment?
Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide have cemented their status as two of the most successful drugs in recent memory. Recent projections have estimated that the drug class could fetch $44 billion by 2030 and $71 billion by 2032. But GLP-1 sales could potentially reach greater heights as these therapies move beyond…